Literature DB >> 10196103

Irreversible caspase inhibitors: tools for studying apoptosis.

J C Wu1, L C Fritz.   

Abstract

Irreversible inhibitors of caspase proteases are often used in studies of apoptosis. However, vigorous interpretation of data generated with irreversible inhibitors requires quantitative analysis of their effects on enzyme kinetics. A simple method for the quantitative analysis of affinity irreversible inhibitors is introduced. The method allows simultaneous measurement of the dissociation constant Ki for the reversible binding to a caspase and the first-order rate constant k3 for the subsequent in situ covalent reaction that follows the noncovalent binding. The Ki value provides information regarding the affinity of an inhibitor for the enzyme, whereas the k3 value provides a measure of the in situ reactivity between the reactive functional groups of the bound inhibitor and the nearby nucleophilic side chain at the protease active site. This two-step kinetic analysis offers a more complete description of the characteristics of an irreversible inhibitor than does the commonly used second-order rate constant. The method has been applied to a library of irreversible caspase inhibitors. We demonstrate how the resulting quantitative inhibitory constants can be used to identify key caspase activities responsible for apoptosis in specific cellular models. Copyright 1999 Academic Press.

Mesh:

Substances:

Year:  1999        PMID: 10196103     DOI: 10.1006/meth.1999.0746

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  9 in total

Review 1.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

2.  Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.

Authors:  Yunxia Tao; Jun Kim; Sarah Faubel; Joe C Wu; Sandor A Falk; Robert W Schrier; Charles L Edelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-29       Impact factor: 11.205

3.  Preparation of the caspase-3/7 substrate Ac-DEVD-pNA by solution-phase peptide synthesis.

Authors:  Quinn P Peterson; David R Goode; Diana C West; Rachel C Botham; Paul J Hergenrother
Journal:  Nat Protoc       Date:  2010-01-28       Impact factor: 13.491

4.  Development of cell death-based method for the selectivity screening of caspase-1 inhibitors.

Authors:  Puneet Chopra; Shashank Gupta; Sunanda G Dastidar; Abhijit Ray
Journal:  Cytotechnology       Date:  2009-08-05       Impact factor: 2.058

5.  Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases.

Authors:  M F van Delft; D P Smith; M H Lahoud; D C S Huang; J M Adams
Journal:  Cell Death Differ       Date:  2009-11-13       Impact factor: 15.828

6.  Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor.

Authors:  D Chauvier; S Renolleau; S Holifanjaniaina; S Ankri; M Bezault; L Schwendimann; C Rousset; R Casimir; J Hoebeke; M Smirnova; G Debret; A-P Trichet; Y Carlsson; X Wang; E Bernard; M Hébert; J-M Rauzier; S Matecki; A Lacampagne; P Rustin; J Mariani; H Hagberg; P Gressens; C Charriaut-Marlangue; E Jacotot
Journal:  Cell Death Dis       Date:  2011-09-01       Impact factor: 8.469

7.  Discovery of indole tetrafluorophenoxymethylketone-based potent novel small molecule inhibitors of caspase-3.

Authors:  Dodheri Syed Samiulla; Andra Naidu; Gummadi Venkateshwar Rao; Murali Ramachandra
Journal:  Org Med Chem Lett       Date:  2012-07-16

8.  Bcl-2-regulated apoptosis and cytochrome c release can occur independently of both caspase-2 and caspase-9.

Authors:  Vanessa S Marsden; Paul G Ekert; Mark Van Delft; David L Vaux; Jerry M Adams; Andreas Strasser
Journal:  J Cell Biol       Date:  2004-06-21       Impact factor: 10.539

Review 9.  Caspases as therapeutic targets.

Authors:  B Howley; H O Fearnhead
Journal:  J Cell Mol Med       Date:  2008-02-24       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.